新辅助化疗治疗进展期胃癌的疗效分析

The Efficacy Analysis in the Treatment of Advanced Gastric Cancer with Neoadjuvant Chemotherapy

摘要: 目的：探讨进展期胃癌应用新辅助化疗的疗效及其安全性。方法：回顾性分析2013年1月至2019年2月间我收治的56例进展期胃癌患者临床资料，采用新辅助化疗，2个治疗周期后进行化疗疗效分析；并评估临床疗效和不良反应。结果：所有患者均顺利完成新辅助化疗(100%)，平均化疗周期为2.48 ± 0.15个周期，化疗方案有SOX方案、DOS方案和FLOT方案。本组病例中CR 3例(5.35%)，PR 30例(53.57%)，SD 15例(26.79%)，PD 8例(14.29%)，有效率58.93%。49例行根治性切除术，4例行姑息性切除术，3例因疾病进展未进行手术。化疗副反应主要有骨髓抑制、恶心呕吐、腹泻、肝功能损害、皮肤过敏。中位存活时间为23.5个月。结论：新辅助化疗疗效安全、副反应低，能给部分进展期胃癌患者带来生存获益。

Abstract: Objective: To investigate the efficacy and safety of neoadjuvant chemotherapy for advanced gastric cancer. Methods: From January 2013 to February 2019, 56 patients with advanced gastric cancer who treated with neoadjuvant chemotherapy were retrospectively analyzed. The efficacy of chemotherapy was analyzed after 2 treatment cycles. Clinical efficacy and adverse reactions were evaluated. Results: All patients successfully completed neoadjuvant chemotherapy (100%) with an average chemotherapy cycle of 2.48 ± 0.15 cycles. The chemotherapy regimen included SOX regimen, DOS regimen and FLOT regimen. In this group, there were 3 cases of CR (5.35%), 30 cases of PR (53.57%), 15 cases of SD (26.79%), and 8 cases of PD (14.29%), with an effective rate of 58.93%. Forty-nine patients underwent radical resection, 4 underwent palliative resection, and 3 did not undergo surgery due to disease progression. The Side effects of chemotherapy mainly include myelosuppression, nausea and vomiting, diarrhea, liver damage, skin allergy. Median survival was 23.5 months. Conclusion: Neoadjuvant chemotherapy is safe and has low side effects. It can bring survival benefit to some patients with advanced gastric cancer.